PH12014501218B1 - Dry coated tablet - Google Patents

Dry coated tablet

Info

Publication number
PH12014501218B1
PH12014501218B1 PH12014501218A PH12014501218A PH12014501218B1 PH 12014501218 B1 PH12014501218 B1 PH 12014501218B1 PH 12014501218 A PH12014501218 A PH 12014501218A PH 12014501218 A PH12014501218 A PH 12014501218A PH 12014501218 B1 PH12014501218 B1 PH 12014501218B1
Authority
PH
Philippines
Prior art keywords
coated tablet
dry coated
active ingredient
outer layer
inner core
Prior art date
Application number
PH12014501218A
Other languages
English (en)
Other versions
PH12014501218A1 (en
Inventor
Tetsuya Kawano
Yasushi Mima
Yumiko Ishii
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PH12014501218A1 publication Critical patent/PH12014501218A1/en
Publication of PH12014501218B1 publication Critical patent/PH12014501218B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Sampling And Sample Adjustment (AREA)
PH12014501218A 2011-11-30 2014-05-29 Dry coated tablet PH12014501218B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011262679 2011-11-30
PCT/JP2012/081583 WO2013081177A1 (en) 2011-11-30 2012-11-29 Dry coated tablet

Publications (2)

Publication Number Publication Date
PH12014501218A1 PH12014501218A1 (en) 2014-09-08
PH12014501218B1 true PH12014501218B1 (en) 2014-09-08

Family

ID=47428946

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014501218A PH12014501218B1 (en) 2011-11-30 2014-05-29 Dry coated tablet

Country Status (14)

Country Link
US (2) US9433632B2 (enExample)
EP (1) EP2785331B1 (enExample)
JP (1) JP5925318B2 (enExample)
KR (1) KR101952478B1 (enExample)
CN (1) CN104080446B (enExample)
AR (1) AR089032A1 (enExample)
CA (1) CA2857457C (enExample)
ES (1) ES2561098T3 (enExample)
MY (1) MY186477A (enExample)
PH (1) PH12014501218B1 (enExample)
SG (1) SG11201402400YA (enExample)
TW (1) TWI630002B (enExample)
UY (1) UY34478A (enExample)
WO (1) WO2013081177A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6289367B2 (ja) 2012-06-05 2018-03-07 武田薬品工業株式会社 有核錠
KR20160010595A (ko) 2013-05-21 2016-01-27 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
EP3204495B1 (en) * 2014-10-08 2020-04-22 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
UA124663C2 (uk) * 2015-07-30 2021-10-27 Такеда Фармасьютікал Компані Лімітед Таблетка
US20210113475A1 (en) * 2017-04-18 2021-04-22 Sensient Colors Llc Dosage form coating composition and method of making and using the same
JP7710850B2 (ja) * 2017-12-29 2025-07-22 ラクソン メディカル アーゲー 薬物送達システム
KR20190092805A (ko) 2018-01-31 2019-08-08 삼진제약주식회사 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
CN116419750A (zh) * 2020-09-07 2023-07-11 西普鲁梅有限公司 改进的glp-1受体激动剂的药物制剂
EP4091605A1 (en) 2021-05-19 2022-11-23 G.L. Pharma GmbH Pharmaceutical tablet comprising acetylsalicylic acid
KR20230149188A (ko) 2022-04-19 2023-10-26 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
CN119072315A (zh) 2022-04-19 2024-12-03 韩美药品株式会社 包含乙酰水杨酸和质子泵抑制剂的药物组合物
KR20240043707A (ko) 2022-09-27 2024-04-03 한미약품 주식회사 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
JP2820829B2 (ja) 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH04346930A (ja) 1991-05-25 1992-12-02 Sumitomo Pharmaceut Co Ltd 安定なアスピリン腸溶錠
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 2−(2−ピリジルメチルスルフィニル)ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
US20060182802A1 (en) 1998-07-28 2006-08-17 Toshihiro Shimizu Rapidly disintegrable solid preparation
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
DE60124692T2 (de) 2000-04-28 2007-09-13 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
ES2521690T3 (es) 2000-05-15 2014-11-13 Takeda Pharmaceutical Company Limited Procedimiento para producir un cristal de (R)-2-[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridil]metil]sulfinil]-bencimidazol
CA2436825C (en) 2000-12-01 2011-01-18 Takeda Chemical Industries, Ltd. Process for the crystallization of (r)- or (s)-lansoprazole
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (en) * 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20080166407A1 (en) * 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
DE102005047616A1 (de) 2005-10-05 2007-05-31 Bayer Healthcare Ag Kombination
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
JP5529404B2 (ja) 2008-09-05 2014-06-25 東和薬品株式会社 アスピリン腸溶錠
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
WO2011144994A1 (en) 2010-05-21 2011-11-24 Lupin Limited Pharmaceutical compositions of nsaid and acid inhibitor
MY180677A (en) * 2010-12-03 2020-12-05 Takeda Pharmaceuticals Co Orally disintegrating tablet

Also Published As

Publication number Publication date
PH12014501218A1 (en) 2014-09-08
JP5925318B2 (ja) 2016-05-25
EP2785331A1 (en) 2014-10-08
TW201328726A (zh) 2013-07-16
US20170014347A1 (en) 2017-01-19
US9433632B2 (en) 2016-09-06
US20140335181A1 (en) 2014-11-13
CA2857457C (en) 2018-05-01
TWI630002B (zh) 2018-07-21
UY34478A (es) 2013-06-28
JP2014533656A (ja) 2014-12-15
ES2561098T3 (es) 2016-02-24
SG11201402400YA (en) 2014-06-27
WO2013081177A1 (en) 2013-06-06
CN104080446B (zh) 2018-06-29
HK1197581A1 (zh) 2015-01-30
EP2785331B1 (en) 2015-11-18
MY186477A (en) 2021-07-22
US10238605B2 (en) 2019-03-26
KR101952478B1 (ko) 2019-02-26
KR20140096157A (ko) 2014-08-04
CA2857457A1 (en) 2013-06-06
AR089032A1 (es) 2014-07-23
CN104080446A (zh) 2014-10-01

Similar Documents

Publication Publication Date Title
PH12014501218B1 (en) Dry coated tablet
MY189306A (en) Tablet
MY184077A (en) Orally disintegrable tablet
CR20130287A (es) Tableta oralmente desintegradora
PH12016500121A1 (en) Pharmaceutical tablet comprising acetylsalicyclic acid and clopidogrel
CR20140485A (es) Formulacion de farmaco de liberacion retardada
CR20160192A (es) Formulación de farmaco de liberación retardada
ECSP13012825A (es) Tableta oralmente desintegradora
CL2013001979A1 (es) Composicion farmaceutica en tableta, que comprende compuestos inmunosupresores, moduladores del receptor s1p, que incluye tambien un desecante y se recubre con una barrera a la humedad.
MX369315B (es) Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos.
IN2015DN04161A (enExample)
WO2012127495A3 (en) Pharmaceutical composition and process for preparation thereof
PH12017500282A1 (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
MX361275B (es) Formulacion de capsula de acido 5-aminosalicilico.
TW201613584A (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
TH153153A (th) ยาเม็ดเคลือบแห้ง
UA59388U (ru) Комбинированный лекарственный препарат анальгетического, противовоспалительного и жаропонижающего действия
NZ628867A (en) Pharmaceutical formulation containing flupirtine
TH169516A (th) ยาเม็ดชนิดแตกตัวได้ในช่องปาก